27
May

On Friday afternoon Provectus Biopharmaceuticals spread the word that the FDA had dissed its tumor drug PV-10, refusing to provide a breakthrough therapy designation based on the data it had seen. And Tuesday morning, as its stock began trading, investors inflicted a drubbing on the stock, sending shares down by 80%.

…read more

Source: Provectus shares crushed in rout after FDA spurns tumor drug

    

0 No comments